基于YTHDC2、IGF2BP2和HNRNPC的头颈部鳞状细胞癌N6-甲基腺苷风险模型构建及临床应用评估

doi:10.7518/hxkq.2022.06.012

华西口腔医学杂志 ›› 2022, Vol. 40 ›› Issue (6): 704-709.doi: 10.7518/hxkq.2022.06.012

基于YTHDC2、IGF2BP2和HNRNPC的头颈部鳞状细胞癌N6-甲基腺苷风险模型构建及临床应用评估

岳蔷薇(), 徐乐, 张东升()

山东第一医科大学附属省立医院口腔科，济南 250021

收稿日期:2022-02-21 修回日期:2022-09-08 出版日期:2022-12-01 发布日期:2022-11-23
通讯作者: 张东升 E-mail:32161343@qq.com;ds63zhang@sdu.edu.cn
作者简介:岳蔷薇，主管护师，学士，E-mail：32161343@qq.com
基金资助:
山东省自然科学基金面上项目(ZR2021MH353)

Construction and clinical evaluation of N6-methyladenosine risk signature of YTHDC2, IGF2BP2, and HNRNPC in head and neck squamous cell carcinoma

Yue Qiangwei(), Xu Le, Zhang Dongsheng.()

Dept. of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China

Received:2022-02-21 Revised:2022-09-08 Online:2022-12-01 Published:2022-11-23
Contact: Zhang Dongsheng. E-mail:32161343@qq.com;ds63zhang@sdu.edu.cn
Supported by:
Shandong Provincial Natural Science Foundation(ZR2021MH353);Correspondence: Zhang Dongsheng, E-mail: ds63zhang@sdu.edu.cn

摘要/Abstract

摘要：

目的利用生物信息学技术构建头颈部鳞状细胞癌（HNSCC）N6-甲基腺苷（m⁶A）调节因子模型，进行预后及肿瘤免疫微环境评估。方法利用R语言对癌症基因组图谱（TCGA）数据库HNSCC患者进行m⁶A调节因子风险预后模型构建，然后对不同风险组进行差异基因分析、细胞类型富集分析和临床相关性分析。结果 HNSCC中15个m⁶A调节因子表达异常，根据异常表达基因构建了HNSCC YTHDC2、IGF2BP2和HNRNPC三基因独立预后风险模型，其中高风险组免疫抑制相关因子及免疫细胞显著增多，抗肿瘤免疫相关因子及免疫细胞减少，呈现促肿瘤的免疫微环境。结论联合YTHDC2、IGF2BP2和HNRNPC的m⁶A调节因子风险预后模型可以有效评估HNSCC患者预后及肿瘤免疫浸润状态。

关键词: 头颈部鳞状细胞癌, N6-甲基腺苷, 预后风险模型, 肿瘤免疫微环境, 生物信息学分析

Abstract:

Objective This work aimed to construct N6-methyladenosine (m⁶A) regulator-based prognostic signature and evaluate the prognostic value and the intervention on tumor immune microenvironment of this m⁶A risk signature. Methods Using transcriptome and clinical data of head and neck squamous cell carcinoma (HNSCC) from The Cancer Genome Atlas (TCGA), we profiled m⁶A regulators and constructed an m⁶A risk signature. The relationship between m⁶A modulation and immune function was studied by differential gene expression, cell type enrichment, and correlation analyses. Results Fifteen m⁶A regulators had aberrant expression in HNSCC. A three-gene m⁶A prognostic signature (i.e., YTHDC2, IGF2BP2, and HNRNPC) was constructed and identified as an independent prognostic indicator for HNSCC. The m⁶A regulator signature-based high-risk group revealed pro-tumoral immune microenvironment due to the dysregulation of immune-related gene expression, abnormal enrichment of multiple immunocytes, and production of immunoregulatory factors. Conclusion This comprehensive analysis of m⁶A regulators and tumor immune landscape in HNSCC revealed that the m⁶A signature of YTHDC2, IGF2BP2, and HNRNPC could serve as a promising biomarker for monitoring HNSCC development and may be a potential target for tumor therapy in the future.

Key words: head and neck squamous cell carcinoma, N6-methyladenosine, prognostic risk signature, tumor immune microenvironment, bioinformatic analysis

中图分类号:

Q 786

岳蔷薇, 徐乐, 张东升. 基于YTHDC2、IGF2BP2和HNRNPC的头颈部鳞状细胞癌N6-甲基腺苷风险模型构建及临床应用评估[J]. 华西口腔医学杂志, 2022, 40(6): 704-709.

Yue Qiangwei, Xu Le, Zhang Dongsheng.. Construction and clinical evaluation of N6-methyladenosine risk signature of YTHDC2, IGF2BP2, and HNRNPC in head and neck squamous cell carcinoma[J]. West China Journal of Stomatology, 2022, 40(6): 704-709.

图/表 4

图 1

图 2

表 1

图 3

参考文献 24

1	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
2	Cramer JD, Burtness B, Le QT, et al. The changing therapeutic landscape of head and neck cancer[J]. Nat Rev Clin Oncol, 2019, 16(11): 669-683.
3	Huang H, Weng H, Chen J. m6A modification in Coding and Non-coding RNAs: roles and therapeutic implications in cancer[J]. Cancer Cell, 2020, 37(3): 270-288.
4	Liu J, Li K, Cai J, et al. Landscape and regulation of m6A and m6Am methylome across human and mouse tissues[J]. Mol Cell, 2020, 77(2): 426-440.e6.
5	Zhao X, Cui L. Development and validation of a m6A RNA methylation regulators-based signature for predic-ting the prognosis of head and neck squamous cell carcinoma[J]. Am J Cancer Res, 2019, 9(10): 2156-2169.
6	Terlizzi M, Casolaro V, Pinto A, et al. Inflammasome: cancer's friend or foe[J]. Pharmacol Ther, 2014, 143(1): 24-33.
7	Zhang B, Wu Q, Li B, et al. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer[J]. Mol Cancer, 2020, 19(1): 53.
8	Han D, Liu J, Chen C, et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells[J]. Nature, 2019, 566(7743): 270-274.
9	Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape[J]. Genome Biol, 2017, 18(1): 220.
10	Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer[J]. Nat Rev Cancer, 2018, 18(5): 269-282.
11	Li Y, Xiao J, Bai J, et al. Molecular characterization and clinical relevance of m6A regulators across 33 cancer types[J]. Mol Cancer, 2019, 18(1): 137.
12	Shriwas O, Priyadarshini M, Samal SK, et al. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m6A-demethylation of FOXM1 and NA-NOG[J]. Apoptosis, 2020, 25(3/4): 233-246.
13	Zhao W, Cui Y, Liu L, et al. METTL3 facilitates oral squamous cell carcinoma tumorigenesis by enhancing c-Myc stability via YTHDF1-mediated m6A modification[J]. Mol Ther Nucleic Acids, 2020, 20: 1-12.
14	Ban Y, Tan P, Cai J, et al. LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma[J]. Mol Oncol, 2020, 14(6): 1282-1296.
15	Tanabe A, Konno J, Tanikawa K, et al. Transcriptional machinery of TNF-α-inducible YTH domain containing 2 (YTHDC2) gene[J]. Gene, 2014, 535(1): 24-32.
16	Fanale D, Iovanna JL, Calvo EL, et al. Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility[J]. Expert Opin Ther Targets, 2014, 18(8): 841-850.
17	Cui Q, Shi H, Ye P, et al. m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells[J]. Cell Rep, 2017, 18(11): 2622-2634.
18	Cheng M, Sheng L, Gao Q, et al. The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network[J]. Oncogene, 2019, 38(19): 3667-3680.
19	Wu Y, Zhao W, Liu Y, et al. Function of HNRNPC in breast cancer cells by controlling the dsRNA-induced interferon response[J]. EMBO J, 2018, 37(23): e99017.
20	Fischl H, Neve J, Wang Z, et al. hnRNPC regulates cancer-specific alternative cleavage and polyadenylation profiles[J]. Nucleic Acids Res, 2019, 47(14): 7580-7591.
21	Li T, Hu PS, Zuo Z, et al. METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma[J]. Mol Cancer, 2019, 18(1): 112.
22	Liu J, Zhang X, Chen K, et al. CCR7 Chemokine receptor-inducible lnc-Dpf3 restrains dendritic cell migration by inhibiting HIF-1α-mediated glycolysis[J]. Immunity, 2019, 50(3): 600-615.
23	Winkler R, Gillis E, Lasman L, et al. m6A modification controls the innate immune response to infection by targeting type I interferons[J]. Nat Immunol, 2019, 20(2): 173-182.
24	Wang H, Hu X, Huang M, et al. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation[J]. Nat Commun, 2019, 10(1): 1898.

临床特征		风险分组		P值
临床特征		低风险	高风险	P值
年龄/岁	≤65	121	135	0.611
	>65	65	65
性别	女性	59	44	0.031*
	男性	127	156
临床分期	Ⅰ期	17	5	0.047*
	Ⅱ期	22	26
	Ⅲ期	34	38
	Ⅳ期	113	131
病理分级	1级	34	15	0.002***
	2级	118	128
	3级	33	57
	4级	1	0

[1]	曾小丽, 李生娇, 单铮男, 殷俊豪, 姜吉蕊, 郑章龙, 李家. 基于基因芯片整合分析筛选慢性牙周炎相关基因和转录因子[J]. 华西口腔医学杂志, 2021, 39(6): 633-641.
[2]	朱震坤, 王羽裳, 徐欣. 沉默热休克蛋白27基因对头颈部鳞状细胞癌细胞生物学行为的影响[J]. 华西口腔医学杂志, 2020, 38(2): 139-144.
[3]	崔广学,高晓磊,梁新华. 人乳头瘤病毒相关头颈部鳞状细胞癌侵袭转移的分子机制[J]. 华西口腔医学杂志, 2018, 36(5): 544-551.
[4]	李鹏, 李文鹿, 齐金星. 基质细胞衍生因子1通过整合素αvβ3-CXC族趋化因子受体4和7诱导头颈部鳞状细胞癌转移的研究[J]. 华西口腔医学杂志, 2018, 36(4): 398-403.
[5]	崔广学, 高晓磊, 梁新华. 人乳头瘤状病毒在头颈部鳞状细胞癌中的研究进展[J]. 华西口腔医学杂志, 2017, 35(2): 187-191.

基于YTHDC2、IGF2BP2和HNRNPC的头颈部鳞状细胞癌N6-甲基腺苷风险模型构建及临床应用评估

Construction and clinical evaluation of N6-methyladenosine risk signature of YTHDC2, IGF2BP2, and HNRNPC in head and neck squamous cell carcinoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 24

相关文章 5

编辑推荐

Metrics

本文评价